118863-62-0 Usage
Description
3-(4-Bromophenyl)-4H-1,2,4-triazole is a heterocyclic chemical compound with the molecular formula C7H5BrN4. It features a five-membered triazole ring composed of two carbon atoms and three nitrogen atoms, with an additional bromophenyl group attached. This unique structure positions it as a versatile building block in organic synthesis and a candidate for pharmaceutical and agricultural applications, including anti-tumor, fungicidal, and insecticidal properties.
Uses
Used in Pharmaceutical Industry:
3-(4-Bromophenyl)-4H-1,2,4-triazole is used as a potential anti-tumor agent for its demonstrated activity in cancer research. It is being explored for its ability to target and inhibit the growth of tumor cells, offering a new avenue for cancer treatment.
Used in Agricultural Industry:
3-(4-Bromophenyl)-4H-1,2,4-triazole is used as a fungicide for its fungicidal properties, helping to protect crops from fungal infections and diseases, thereby improving crop yield and quality.
Used in Pesticide Development:
3-(4-Bromophenyl)-4H-1,2,4-triazole is used as an insecticide due to its insecticidal properties, serving as a component in the development of pesticides to control and eliminate pests that threaten agricultural produce.
Used in Organic Synthesis:
3-(4-Bromophenyl)-4H-1,2,4-triazole is used as a building block in the synthesis of other organic compounds, contributing to the creation of new molecules with various applications in different industries, including pharmaceuticals, materials science, and agrochemicals.
Check Digit Verification of cas no
The CAS Registry Mumber 118863-62-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,8,8,6 and 3 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 118863-62:
(8*1)+(7*1)+(6*8)+(5*8)+(4*6)+(3*3)+(2*6)+(1*2)=150
150 % 10 = 0
So 118863-62-0 is a valid CAS Registry Number.
118863-62-0Relevant articles and documents
GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE
-
Paragraph 001999; 002001, (2021/01/22)
Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.
GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE
-
Paragraph 002041; 002042; 002044, (2019/07/17)
Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.
NOVEL ARYL OR HETEROARYL TRIAZOLONE DERIVATIVES OR SALTS THEREOF, OR PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
-
Paragraph 0227; 0230, (2019/10/15)
The present technology provides aryl or heteroaryl triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The aryl or heteroaryl triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).
